Shaun Chilton – CEO, Clinigen Group, UK
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Address: Janssen, 50-100 Holmers Farm Way, High Wycombe, Buckinghamshire, HP12 4EG, United Kingdom
Tel: +44 (0) 1494 567567
Web: http://www.janssen.co.uk/
In 1947, Ortho Pharmaceuticals was brought into the Johnson & Johnson group of companies and set up a UK base in Lane End, Buckinghamshire.
Johnson & Johnson’s pharmaceutical interests expanded over the next decades with the addition of the Swiss company Cilag Chemie in 1959 and the Belgian company Janssen Pharmaceutica in 1961. Both of these companies had grown from small research laboratories into successful multinationals.
Ortho moved to a site in Saunderton, Buckinghamshire in the early 1950s. Janssen established its first British offices in Marlow, Buckinghamshire, in 1974 and moved to Grove in Oxfordshire a decade later.
Ortho became Ortho Cilag in 1982 and then Cilag in 1988. On 1st January 1995, Cilag and Janssen merged to become Janssen-Cilag Ltd and all operations were transferred to the Saunderton site. In May 2008, the company moved to new offices in High Wycombe.
In September 2000, Ortho Biotech was established, a company specialising in treatments for conditions such as renal disease and cancer.
Tibotec was established in 1994 as a drug discovery laboratory, it evolved to a fully integrated pharmaceutical company focussing on the discovery and the development of new drugs for infectious diseases. In April 2002, Tibotec was acquired by Johnson & Johnson and became a division of Janssen-Cilag.
In 2010, Janssen-Cilag became Janssen and now employs more than 400 people. Its head office is in High Wycombe, Buckinghamshire and also has an office in Dublin.
Janssen is one of the world’s leading research-based pharmaceutical companies, with operations throughout the world. In the UK, Janssen employs more than 400 people.
The company is committed to delivering great medicines and has introduced a range of innovative treatments that can make an important difference to the lives of patients with serious health conditions such as schizophrenia, epilepsy, multiple myeloma and HIV/AIDS. Janssen has one of the strongest development pipelines in the industry with research now focusing on five key areas. These key areas are: neuroscience, oncology, immunology, metabolism and infectious diseases.
A British success story, Clinigen Group provides companies with services in portfolio and product lifecycle management on a global basis. Its CEO, Shaun Chilton, talks to us about the value…
Having recently joined the UK operations of AstraZeneca after a varied international career, Laurent Abuaf shares his vision of the UK as a life sciences reference market and his take…
Heading Accord Healthcare’s European, Middle East and North African operations, James Burt highlights the rapid growth the company has achieved within the region and how it has reached an impressive…
Promoting the UK’s capital in times of Brexit, Laura Citron, CEO at London & Partners, the international promotional agency of the Mayor of London, stresses the critical importance life sciences…
Erik Nordkamp, managing director of Pfizer UK, has been confirmed as the new president of the Association of the British Pharmaceutical Industry (ABPI). With UK life sciences still uncertain as…
Craig Wallace established the UK affiliate of Santen, the Japanese ophthalmology company, in 2014. Wallace describes the journey Santen has been on so far in the UK, as well as…
Britain, home of the discovery of the world’s first ever vaccine, has long been championing a pharma sub-segment forecast to reach a global market value of USD 49.27 billion by…
Thomas Bo Bjorn Klee, managing director of Lundbeck UK and Ireland, describes the global restructuring program Lundbeck initiated two years ago to ensure value creation, build on unique strengths and…
Having recently been able to present positive data for their lead technology IMCgp100 in uveal melanoma at the American Society of Clinical Oncology (ASCO), Immunocore looks at its future as…
Erik Nordkamp, managing director of Pfizer UK shares his thoughts on the future of healthcare and the role that Pfizer and the UK can play in shaping it. He explains…
Stewart Pearce, managing director of Otsuka UK and Ireland since 2017 discloses how he built up a leadership team fit for the Otsuka of 2023 and highlights what he appreciates…
As the UK extracts itself from the European Union, key figures from the country’s life sciences sector are split on the implications of Brexit for their industry. “The UK pharmaceutical…
See our Cookie Privacy Policy Here